Book
A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine
| العنوان: | A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine |
|---|---|
| المؤلفون: | Peveler, R., Kendrick, A., Buxton, M., Longworth, L., Baldwin, D., Moore, M., Chatwin, J., Goddard, J., Thornett, A., Smith, H., Campbell, M., Thompson, C. |
| بيانات النشر: | National Coordinating Centre for Health Technology Assessments |
| سنة النشر: | 2005 |
| المجموعة: | University of Southampton: e-Prints Soton |
| الوصف: | Aim/ Principal Research Question - The main aim of the “AHEAD” study was to determine the relative cost-effectiveness of three classes of antidepressants: tricyclics (TCAs), selective serotonin reuptake inhibitors (SSRIs), and the tricyclic-related antidepressant lofepramine, as first choice treatments for depression in UK primary care. Factors of interest - This is the first randomised prospective study in UK primary care to address this question. Most previous work on this topic has relied upon modelling and/or post hoc analysis of data collected for other purposes. The only other published trial of this type was conducted in HMOs in the United States. Methods - The study was an open label, pragmatic controlled trial with three randomised arms and one preference arm. Patients were followed up for a total of 12 months. Patients were randomised to receive a tricyclic antidepressant (amitriptyline, dothiepin, or imipramine), a selective serotonin reuptake inhibitor (fluoxetine, sertraline, or paroxetine), or lofepramine. Standardised recommendations about dose and dose escalation based on the BNF were issued to GPs. Cost effectiveness was based upon an analysis of direct costs from an NHS perspective. Sample groups - The study was carried out in UK primary care: 73 practices in urban and rural areas in Hampshire, Wiltshire, Dorset, Sussex, and Surrey agreed initially to take part. Patients with a new episode of depressive illness according to GP diagnosis were recruited. A total of 388 patients were referred to the study team by 87 GPs from 55 practices. Incremental cost-effectiveness ratios and cost-effectiveness acceptability curves (CEACs) were computed. Estimates were bootstrapped with 5000 replications. Outcome measures - At baseline the Clinical Interview Schedule, Revised (CIS-R PROQSY computerised version) was administered to establish symptom profiles. Outcome measures over 12 month follow-up included the Hospital Anxiety and Depression Scale self-rating of depression (HAD-D), CIS-R, EuroQol (EQ-5D) for ... |
| نوع الوثيقة: | book |
| اللغة: | unknown |
| Relation: | Peveler, R., Kendrick, A., Buxton, M., Longworth, L., Baldwin, D., Moore, M., Chatwin, J., Goddard, J., Thornett, A., Smith, H., Campbell, M. and Thompson, C. , NCCHTA (2005) A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine (Health Technology Assessment, Vol 9: number 16) Southampton, UK. National Coordinating Centre for Health Technology Assessments 152pp. (doi:10.3310/hta9160 ). |
| الاتاحة: | https://eprints.soton.ac.uk/46435/ http://www.hta.ac.uk/fullmono/mon916.pdf |
| رقم الانضمام: | edsbas.DDE9402A |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |